Mazin Derzi

Current nonclinical testing paradigms in support of safe clinical trials: An IQ Consortium DruSafe perspective

Lynne Butler, Peggy Guzzie‐Peck, James Hartke et al. · Regulatory Toxicology and Pharmacology · 2017 · 44 citations

Safe Clinical Trials, Clinical Effectiveness, Real World Evidence +10

Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade® (Infliximab)

Mazin Derzi, Theodore R. Johnson, Ahmed Shoieb et al. · Advances in Therapy · 2016 · 36 citations · Full text

An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin®), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension

Keith Owen, David M. Cross, Mazin Derzi et al. · Regulatory Toxicology and Pharmacology · 2012 · 26 citations

Hypertension, Pulmonary Arterial Hypertension, Pulmonary Circulation +9

Comparative nonclinical assessments of the biosimilar PF-06410293 and originator adalimumab

Mazin Derzi, Ahmed Shoieb, Sharon L. Ripp et al. · Regulatory Toxicology and Pharmacology · 2020 · 19 citations · Full text

Immunology, Pathology, Cell Death +18

Industry Perspective on Biomarker Development and Qualification

Cory V. Gerlach, Mazin Derzi, Shashi K. Ramaiah et al. · Clinical Pharmacology & Therapeutics · 2017 · 15 citations

Biotechnology Companies, Engineering, Biomarker (Medicine) +21